Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses

Ming Lun Yeh; Chao Hung Hung; Jee Fu Huang; Chun Jen Liu; Chuan Mo Lee; Chia Yen Dai; Jing Houng Wang; Zu Yau Lin; Sheng Nan Lu; Tsung Hui Hu; Ming Lung Yu; Jia Horng Kao; Wan Long Chuang; Pei Jer Chen; Ding Shinn Chen

doi:10.1371/journal.pone.0020752

Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses

Ming Lun Yeh, Chao Hung Hung, Jee Fu Huang, Chun Jen Liu^*, Chuan Mo Lee, Chia Yen Dai, Jing Houng Wang, Zu Yau Lin, Sheng Nan Lu, Tsung Hui Hu, Ming Lung Yu, Jia Horng Kao, Wan Long Chuang, Pei Jer Chen, Ding Shinn Chen

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

20 Scopus citations

Abstract

Background: Interferon-α/ribavirin combination therapy might promote hepatitis B surface antigen (HBsAg) seroclearance in patients dually infected with hepatitis B and C viruses (HBV/HCV), but the long-term effect remains unclear. We aimed to investigate the rate of and the factors associated with HBsAg seroclearance during long-term follow-up after interferon-α/ribavirin combination therapy in HBV/HCV dually-infected patients. Methodology/Principal Findings: Eighty-one patients who received interferon-α/ribavirin combination therapy for 24 weeks with a follow-up period of >24 weeks were enrolled. HBV serological markers and HBV DNA were determined every 6 months. Early and late HBsAg seroclearance were defined as HBsAg loss in less or more than 6 months after end-of-treatment, respectively. Fifteen (18.5%) patients had HBsAg seroclearance during a mean follow-up period of 3.4 (0.5-5.1) years. The 5-year cumulative incidence was 25.6%. Baseline cirrhosis and HBV DNA negativity 1 year after end-of-treatment were independently predictive of HBsAg seroclearance with an odds ratio (OR), 95% confidence intervals (CI) of 16.6, 1.8-153 and 9.2, 1.4-62.1, respectively, by Cox regression hazard analysis. Four patients developed early and 11 developed late HBsAg seroclearance, respectively. Cox regression hazard analysis showed no factor was associated with early HBsAg seroclearance, whilst HBV DNA negativity 1 year after end-of-treatment was the only significant factor predicting late HBsAg loss (OR, 43.0; CI, 2.5-745). Five patients had HBsAg seroconversion with a 5-year cumulative incidence of 8.3%. HBV DNA negativity at baseline and one year after EOT had a trend for HBsAg seroconversion. HCV response did not correlate to HBsAg loss. Conclusions: We demonstrated that interferon-α/ribavirin had long-term effect on HBsAg seroclearance in dually HBV/HCV-infected patients. Baseline cirrhosis and seroclearance of HBV DNA 1 year after end-of-treatment were significant factors associated with HBsAg seroclearance.

Original language	English
Article number	e20752
Journal	PLoS ONE
Volume	6
Issue number	6
DOIs	https://doi.org/10.1371/journal.pone.0020752
State	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0020752

Cite this

Yeh, M. L., Hung, C. H., Huang, J. F., Liu, C. J., Lee, C. M., Dai, C. Y., Wang, J. H., Lin, Z. Y., Lu, S. N., Hu, T. H., Yu, M. L., Kao, J. H., Chuang, W. L., Chen, P. J., & Chen, D. S. (2011). Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS ONE, 6(6), Article e20752. https://doi.org/10.1371/journal.pone.0020752

@article{5308e60b8b9645238888c773805803b5,

title = "Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses",

abstract = "Background: Interferon-α/ribavirin combination therapy might promote hepatitis B surface antigen (HBsAg) seroclearance in patients dually infected with hepatitis B and C viruses (HBV/HCV), but the long-term effect remains unclear. We aimed to investigate the rate of and the factors associated with HBsAg seroclearance during long-term follow-up after interferon-α/ribavirin combination therapy in HBV/HCV dually-infected patients. Methodology/Principal Findings: Eighty-one patients who received interferon-α/ribavirin combination therapy for 24 weeks with a follow-up period of >24 weeks were enrolled. HBV serological markers and HBV DNA were determined every 6 months. Early and late HBsAg seroclearance were defined as HBsAg loss in less or more than 6 months after end-of-treatment, respectively. Fifteen (18.5%) patients had HBsAg seroclearance during a mean follow-up period of 3.4 (0.5-5.1) years. The 5-year cumulative incidence was 25.6%. Baseline cirrhosis and HBV DNA negativity 1 year after end-of-treatment were independently predictive of HBsAg seroclearance with an odds ratio (OR), 95% confidence intervals (CI) of 16.6, 1.8-153 and 9.2, 1.4-62.1, respectively, by Cox regression hazard analysis. Four patients developed early and 11 developed late HBsAg seroclearance, respectively. Cox regression hazard analysis showed no factor was associated with early HBsAg seroclearance, whilst HBV DNA negativity 1 year after end-of-treatment was the only significant factor predicting late HBsAg loss (OR, 43.0; CI, 2.5-745). Five patients had HBsAg seroconversion with a 5-year cumulative incidence of 8.3%. HBV DNA negativity at baseline and one year after EOT had a trend for HBsAg seroconversion. HCV response did not correlate to HBsAg loss. Conclusions: We demonstrated that interferon-α/ribavirin had long-term effect on HBsAg seroclearance in dually HBV/HCV-infected patients. Baseline cirrhosis and seroclearance of HBV DNA 1 year after end-of-treatment were significant factors associated with HBsAg seroclearance.",

author = "Yeh, {Ming Lun} and Hung, {Chao Hung} and Huang, {Jee Fu} and Liu, {Chun Jen} and Lee, {Chuan Mo} and Dai, {Chia Yen} and Wang, {Jing Houng} and Lin, {Zu Yau} and Lu, {Sheng Nan} and Hu, {Tsung Hui} and Yu, {Ming Lung} and Kao, {Jia Horng} and Chuang, {Wan Long} and Chen, {Pei Jer} and Chen, {Ding Shinn}",

year = "2011",

doi = "10.1371/journal.pone.0020752",

language = "英语",

volume = "6",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "6",

}

Yeh, ML, Hung, CH, Huang, JF, Liu, CJ, Lee, CM, Dai, CY, Wang, JH, Lin, ZY, Lu, SN, Hu, TH, Yu, ML, Kao, JH, Chuang, WL, Chen, PJ & Chen, DS 2011, 'Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses', PLoS ONE, vol. 6, no. 6, e20752. https://doi.org/10.1371/journal.pone.0020752

TY - JOUR

T1 - Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses

AU - Yeh, Ming Lun

AU - Hung, Chao Hung

AU - Huang, Jee Fu

AU - Liu, Chun Jen

AU - Lee, Chuan Mo

AU - Dai, Chia Yen

AU - Wang, Jing Houng

AU - Lin, Zu Yau

AU - Lu, Sheng Nan

AU - Hu, Tsung Hui

AU - Yu, Ming Lung

AU - Kao, Jia Horng

AU - Chuang, Wan Long

AU - Chen, Pei Jer

AU - Chen, Ding Shinn

PY - 2011

Y1 - 2011

N2 - Background: Interferon-α/ribavirin combination therapy might promote hepatitis B surface antigen (HBsAg) seroclearance in patients dually infected with hepatitis B and C viruses (HBV/HCV), but the long-term effect remains unclear. We aimed to investigate the rate of and the factors associated with HBsAg seroclearance during long-term follow-up after interferon-α/ribavirin combination therapy in HBV/HCV dually-infected patients. Methodology/Principal Findings: Eighty-one patients who received interferon-α/ribavirin combination therapy for 24 weeks with a follow-up period of >24 weeks were enrolled. HBV serological markers and HBV DNA were determined every 6 months. Early and late HBsAg seroclearance were defined as HBsAg loss in less or more than 6 months after end-of-treatment, respectively. Fifteen (18.5%) patients had HBsAg seroclearance during a mean follow-up period of 3.4 (0.5-5.1) years. The 5-year cumulative incidence was 25.6%. Baseline cirrhosis and HBV DNA negativity 1 year after end-of-treatment were independently predictive of HBsAg seroclearance with an odds ratio (OR), 95% confidence intervals (CI) of 16.6, 1.8-153 and 9.2, 1.4-62.1, respectively, by Cox regression hazard analysis. Four patients developed early and 11 developed late HBsAg seroclearance, respectively. Cox regression hazard analysis showed no factor was associated with early HBsAg seroclearance, whilst HBV DNA negativity 1 year after end-of-treatment was the only significant factor predicting late HBsAg loss (OR, 43.0; CI, 2.5-745). Five patients had HBsAg seroconversion with a 5-year cumulative incidence of 8.3%. HBV DNA negativity at baseline and one year after EOT had a trend for HBsAg seroconversion. HCV response did not correlate to HBsAg loss. Conclusions: We demonstrated that interferon-α/ribavirin had long-term effect on HBsAg seroclearance in dually HBV/HCV-infected patients. Baseline cirrhosis and seroclearance of HBV DNA 1 year after end-of-treatment were significant factors associated with HBsAg seroclearance.

AB - Background: Interferon-α/ribavirin combination therapy might promote hepatitis B surface antigen (HBsAg) seroclearance in patients dually infected with hepatitis B and C viruses (HBV/HCV), but the long-term effect remains unclear. We aimed to investigate the rate of and the factors associated with HBsAg seroclearance during long-term follow-up after interferon-α/ribavirin combination therapy in HBV/HCV dually-infected patients. Methodology/Principal Findings: Eighty-one patients who received interferon-α/ribavirin combination therapy for 24 weeks with a follow-up period of >24 weeks were enrolled. HBV serological markers and HBV DNA were determined every 6 months. Early and late HBsAg seroclearance were defined as HBsAg loss in less or more than 6 months after end-of-treatment, respectively. Fifteen (18.5%) patients had HBsAg seroclearance during a mean follow-up period of 3.4 (0.5-5.1) years. The 5-year cumulative incidence was 25.6%. Baseline cirrhosis and HBV DNA negativity 1 year after end-of-treatment were independently predictive of HBsAg seroclearance with an odds ratio (OR), 95% confidence intervals (CI) of 16.6, 1.8-153 and 9.2, 1.4-62.1, respectively, by Cox regression hazard analysis. Four patients developed early and 11 developed late HBsAg seroclearance, respectively. Cox regression hazard analysis showed no factor was associated with early HBsAg seroclearance, whilst HBV DNA negativity 1 year after end-of-treatment was the only significant factor predicting late HBsAg loss (OR, 43.0; CI, 2.5-745). Five patients had HBsAg seroconversion with a 5-year cumulative incidence of 8.3%. HBV DNA negativity at baseline and one year after EOT had a trend for HBsAg seroconversion. HCV response did not correlate to HBsAg loss. Conclusions: We demonstrated that interferon-α/ribavirin had long-term effect on HBsAg seroclearance in dually HBV/HCV-infected patients. Baseline cirrhosis and seroclearance of HBV DNA 1 year after end-of-treatment were significant factors associated with HBsAg seroclearance.

UR - http://www.scopus.com/inward/record.url?scp=79958713034&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0020752

DO - 10.1371/journal.pone.0020752

M3 - 文章

C2 - 21695152

AN - SCOPUS:79958713034

SN - 1932-6203

VL - 6

JO - PLoS ONE

JF - PLoS ONE

IS - 6

M1 - e20752

ER -

Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this